Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 4/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL29811219 | 1.00 | MEN1 (0.47) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL2228246 | 1.00 | MEN1 (0.47) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL21220103 | 0.95 | MEN1 (0.47) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL21747582 | 0.95 | MEN1 (0.47) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL28049461 | 0.93 | MEN1 (0.48) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL13248912 | 0.93 | — | — | |
| D-Proline SCHEMBL21462052 | 0.93 | BLM (0.52) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL462226 | 0.93 | BLM (0.52) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL718906 | 0.93 | BLM (0.52) | MEN1BLMKMT2ANOS2NOS3 | |
| Proline SCHEMBL2939 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109072135-B | Mixtures of chelating agents and methods for preparing such mixtures | 巴斯夫欧洲公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-107429202-B | Mixtures of chelating agents and methods of making the same | 巴斯夫欧洲公司 | 2020-07-10 | — | — | CN | disclosed |
| CN-111344004-A | Method and medicine for regulating GLP-1/GLP-1R | 泰伦基国际有限公司 | 2020-06-26 | — | — | CN | disclosed |
| EP-3541413-A2 | AQUEOUS PHARMACEUTICAL FORMULATIONS | Polpharma Biologics S.A. (PL) | 2019-09-25 | — | — | EP | disclosed |
| CN-109476640-A | Bicyclic proline compounds | 豪夫迈·罗氏有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-109476628-A | Sulfonyl cyclic alkyl amides compound as TRPA1 regulator | 豪夫迈·罗氏有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-109072135-A | Mixtures of chelating agents and methods for preparing such mixtures | 巴斯夫欧洲公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-105612153-B | Substituted heterocyclic sulfonamide compound as TRPA1 conditioning agents | 豪夫迈·罗氏有限公司 | 2018-09-14 | — | — | CN | disclosed |
| WO-2018091729-A2 | AQUEOUS PHARMACEUTICAL FORMULATIONS | ZAKLADY FARMACEUTYCZNE POLPHARMA SA (PL) | 2018-05-24 | — | — | WO | disclosed |
| CN-107922392-A | 1 (miscellaneous) aryl sulfonyl (pyrrolidines or piperidines) 2 carboxamides derivatives and its purposes as TRPA1 antagonists | 豪夫迈·罗氏有限公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107429202-A | Mixtures of chelating agents and methods of making the same | 巴斯夫欧洲公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-104684899-B | Substituted sulfonamide compounds | 霍夫曼-拉罗奇有限公司 | 2017-07-04 | — | — | CN | disclosed |
| EP-2523688-A1 | ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS | Kirin-Amgen, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088120-A9 | ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS | KIRIN-AMGEN, INC (US) | 2012-08-09 | — | — | WO | disclosed |
| WO-2011088120-A1 | ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS | AMGEN INC. (US) | 2011-07-21 | — | — | WO | disclosed |